Synergistic Effect of Colistin with Selected Antibiotic on Colistin Resistant Pseudomonas aeruginosa Strains Isolated from Clinical Samples
Novelty in Biomedicine,
Vol. 11 No. 4 (2023),
20 November 2023
,
Page 145- 150
https://doi.org/10.22037/nbm.v11i4.38722
Abstract
Background: The spread of antibiotic resistance and the emergence of MDR strains, especially in gram-negative bacteria, has led to combining antibiotics to treat infections caused by these bacteria. The study aimed to evaluate some antibiotics' synergistic effect on multidrug-resistant Pseudomonas aeruginosa isolates isolated from clinical samples between thyroid dysfunction and asymptomatic bacteriuria in women of reproductive and postmenopausal age.
Materials and Methods: P. aeruginosa was isolated from Rasht city hospitals (North of Iran) clinical specimens with multiple antibiotic resistance. The antibiotic resistance of isolates was determined by the disk diffusion method. The screening checklist evaluated the synergistic effects of ciprofloxacin, colistin, meropenem, and gentamicin.
Results: The combination of meropenem and colistin in four isolates was additive, and in two isolates was indifferent. The combined effect of ciprofloxacin and colistin was also incremental in 4 isolates and indifferent in 2 isolates. The combined effect of gentamicin and colistin was indifferent in all selected strains.
Conclusion: Results of this study showed that combinations of colistin with ciprofloxacin and colistin with meropenem were successful against resistant isolates, while a combination of gentamicin and colistin showed no synergistic effect. Since the characteristics of each clinical isolate differ from the other isolates, more study with more isolates is recommended to make any precise and definite recommendation.
- Pseudomonas aeruginosa
- Antibacterial Resistance
- Colistin
- Synergism
- 2023-11-21 (2)
- 2023-11-20 (1)
How to Cite
References
Pal RB, Rodrigues M, Datta S. Role of Pseudomonas in nosocomial infections and biological characterization of local strains. J Biosci Tech. 2010;1(4):170-9.
Adejobi A, Ojo O, Alaka O, Odetoyin B, Onipede A. Antibiotic resistance pattern of Pseudomonas spp. from patients in a tertiary hospital in South-West Nigeria. Germs. 2021;11(2):238.
Arora D, Jindal N, Kumar R, Romit M. Emerging antibiotic resistance in Pseudomonas-A challenge. Int J Pharm Pharm Sci. 2011;3(2):82-4.
Olayinka AT, Onile BA, Olayinka BO. Prevalence of multi-drug resistant (MDR) Pseudomonas aeruginosa isolates in surgical units of Ahmadu Bello University Teaching Hospital, Zaria, Nigeria: an indication for effective control measures. Ann Afr Med. 2004;3(1):13-6.
Olayinka BO, Olonitola OS, Olayinka AT, Agada EA. Antibiotic susceptibility pattern and multiple antibiotic resistance index of Pseudomonas aeruginosa urine isolates from a University Teaching Hospital. African Journal of Clinical and Experimental Microbiology. 2004;5(2):198-202.
Jombo GT, Jonah P, Ayeni JA. Multidrug resistant Pseudomonas aeruginosa in contemporary medical practice: findings from urinary isolates at a Nigerian University Teaching Hospital. Nigerian Journal of Physiological Sciences. 2008;23(1-2) : 105-109.
Salimi H, Oulia P, Yakhchali B, Rastgar LA. Characterization of Pseudomonas aeruginosa in burn patients using PCR-restriction fragment length polymorphism and random amplified polymorphic DNA analysis., IJMS, 2010; 35(3).
Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. Journal of Antimicrobial Chemotherapy. 2002;49(2):229-33.
Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, et al. Further in-creases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J. 2011;52:793-802.
Huh K, Kim J, Cho SY, Ha YE, Joo EJ, Kang CI, et al. Continuous in-crease of the antimicrobial resistance among gram-negative pathogens causing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases (KONSID). Diagn Microbiol Infect Dis 2013;76:477-82.
Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6:589–601.
Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005; 25:11–25.
10. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infectt. 2007; 5:811– 821.
Velkov T, Roberts KD, Thompson PE, Li J. Polymyxins: a new hope in combating Gram-negative superbugs? Future Med Chem. 2016; 8:1017–1025.
Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrobial agents and chemotherapy. 2012;56(9):4856-61.
Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016; 48:592–597.
Goli HR, Nahaei MR, Ahangarzadeh Rezaee M, Hasani A, Samadi Kafil H, Aghazadeh M. Emergence of colistin resistant Pseudomonas aeruginosa at Tabriz hospitals, Iran. Iranian J Microbiol. 2016; 8:62– 69.
Michalopoulos A, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas M. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115–121.
Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U. Framework for optimization of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015; 15:225–234.
Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore PLoS One. 2011; 6:e18485
Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy. 2015; 35:34–42.
Sharma R, Patel S, Abboud C, Diep J, Ly NS, Pogue JM, Kaye KS, Li J, Rao GG. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. Int J Antimicrob Agents. 2017; 49:224 –232.
Jasim R, Schneider EK, Han M, Azad MA, Hussein M, Nowell C, Baker MA, Wang J, Li J, Velkov T. A fresh shine on cystic fibrosis inhalation therapy: antimicrobial synergy of polymyxin B in combination with silver nanoparticles. J Biomed Nanotechnol. 2017;13:447– 457
James J Rahal. Novel Antibiotic Combinations against Infections with AlmostCompletely Resistant Pseudomonas aeruginosa and Acinetoba cter Species, Oxford Journals, Clinical Infectious Diseases, 2006; 43,s95-s99.
Farrar Jr WE, Newsome JK. Mechanism of synergistic effects of β-lactam antibiotic combinations on gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 1973;4(2):109-14.
Prinsloo A, Van Straten AM, Weldhagen GF. Antibiotic synergy profiles of multidrug-resistant Pseudomonas aeruginosa in a nosocomial environment. Southern African Journal of Epidemiology and Infection. 2008;23(3):7-9.
Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. American journal of clinical pathology. 1966;45(4_ts):493-6.
Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrobial agents and chemotherapy. 2003;47(3):1151-3.
Clinical Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests; Approved standard—9th ed. CLSI document M2-A9. 26:1. Clinical Laboratory Standards Institute, Wayne, PA.
Fazeli M, Soleimanjahi H, Ghaemi A, Farzanepour M, Amanzadeh A, Hashemi SR. Efficacy of HPV-16 E7 based vaccine in a TC-1 tumoric animal model of cervical cancer. Cell Journal (Yakhteh). 2011;12(4):483-8.
Kumar SH, De AS, Baveja SM, Gore MA. Prevalence and risk factors of metallo beta -lactamase producing Pseudomonas aeruginosa and Acinetobacter species in burnsand surgical wards in a tertiary care hospital. J Lab Physicians. 2012;4:39–42.
Tsakris A, Poulou A, Kristo I, Pittaras T, Spanakis N, et al. Large dissemina-tion of VIM-2-metallo- beta-lactamase-producing Pseudomonas aeruginosa strainscausing health care-associated community-onset infections. J Clin Microbiol. 2009;47:3524–9.
Marie MA, Krishnappa LG, Alzahrani AJ, Mubaraki MA, Alyousef AA. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multi-drug resistant Acinetobacter baumannii. Bosn J Basic Med Sci. 2015; 15(4): 24-9.
Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;60(2):317-22.
Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, timekill, and checkerboard methods. Diagn Microbiol Infect Dis. 2000;38(1):43-50.
SoltanDallal MM, RastegarLari A, Bakhtiari R, Nikmanesh B, SharifiYazdi M. Synergistic Effect of Ciprofloxacin with Piperacillin, Ceftazidim and Imipenem against Entrococi. J Adv Med Biomed Res. 2014;22(92):23-32.
Sonne M, Jawetz E. Combined action of carbenicillin and gentamicin on Pseudomonas aeruginosa in vitro. Appl Microbiol. 1969;17(6):893-6.
Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, timekill, and checkerboard methods. Diagn Microbiol Infect Dis. 2000;38(1):43-50.
Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. Invitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45(1): 8-18.
- Abstract Viewed: 252 times
- PDF Downloaded: 148 times